Anirban Basu on Muck Rack

Anirban Basu

  • Chief Executive Officer, Sage Policy Group
Baltimore
As seen in: MSN, Arthritis & Rheumatology, Color Research & Application, Nature, Wiley Online Library, Yahoo Canada, Yahoo News Malaysia, Yahoo News New Zealand, ScienceDirect, BMJ Open and
Father, Husband, economist (hold your applause), & CEO of Sage Policy Group. Chief Economist, Associated Builders & Contractors. Read more at Basu.substack.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anirban

Contact Anirban, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Republicans must pivot to relevance in Maryland | GUEST COMMENTARY

|
By Anirban Basu
| Baltimore Sun
With power comes responsibility. In Maryland, power resides primarily in the hands of Democrats, so it comes as little surprise that criticism tends to be angled toward them. The governor is a Democrat. So, too, are both U.S. senators, seven of eight U.S. House representatives, 34 of 47 state senators, and 102 of 141 representatives in the state’s House of Delegates. But those in the minority party have responsibilities and should therefore also be held accountable.
Open in Who Shared Issue with article?

OpEd: Maryland's economy under Gov. Moore is nothing to smile about

|
By Anirban Basu
| Baltimore Business Journal
Maryland has lost jobs and seen the cost of living increase under Gov. Wes Moore, writes Sage Policy Group CEO Anirban Basu.
Open in Who Shared Issue with article?

Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda’s context - Gene Therapy

|
By J. Felipe Montano-Campos, Jennifer E. Adair, Anirban Basu, Lois Bayigga, Ryan R. Hansen, Rachel Bakyayita Kyeyune, Cissy Kityo-Mutuluuza
| Nature
Abstract Blood stem cell gene therapy to treat hemoglobinopathies is beginning to transform health for small numbers of patients in the U.S. and Europe, where these conditions qualify as rare diseases. Yet hemoglobinopathies are common globally, disproportionately affecting low- and middle-income countries (LMICs), creating an ethical imperative to ensure access where disease burden is greatest.
Open in Who Shared Issue with article?
See all 649 licensed articles (661 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Anirban

Contact Anirban, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified